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Tumors comprising the spectrum of hemangiopericytoma/ malignant solitary
fibrous tumor (HPC/SFT) are thought to arise from fibroblasts and represent a small
subset of soft tissue sarcomas. Surgery is typically the treatment of choice for
localized disease, with reported 10-year overall survival rates of 54-89% after
complete surgical resection. However, for the approximately 20% of HPC/SFT
patients who eventually develop local recurrences and/or distant metastases,
options for effective treatment are limited and are poorly defined. Alternative
therapeutic options are therefore needed for improved palliation and disease
control. We hypothesize that HPC/SFT are a spectrum of soft tissue tumors with
unique clinical, pathological, and molecular makeup and clinical behavior.
HPC/SFT respond to unique therapeutic agents that specifically target aberrations
specific to these tumors.
We retrospectively reviewed the characteristics and the clinical outcomes for
all HPC/SFT patients whose tumor specimens have been reviewed at the MD
Anderson Cancer Center from January 1993 to June 2007 by a MD Anderson
pathologist and were treated at the institution with available electronic medical
records. We identified 128 patients, 79 with primary localized disease and 49 with
recurrent and/or metastatic disease. For the 23 patients with advanced HPC/SFT
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who received adriamycin-based, gemcitabine based, or paclitaxel chemotherapy as
first- or second-line therapy, the overall RECIST response rate was 0%.

Most

patients achieved a brief duration of disease stabilization on chemotherapy, with
median progression-free survival (PFS) period of 4.6 months. For the 14 patients
with advanced HPC/SFT who received temozolomide and bevacizumab systemic
therapy, the overall RECIST response rate was 14%, with the overall Choi response
rate of 79%. The median PFS for the cohort was 9.7 months with a median 6month progression free rate of 78.6%. The most frequently observed toxic effect of
temzolomide-bevacizumab therapy was myelosuppression. We have designed a
phase II study to evaluate the safety and efficacy of temozolomide-bevaciumab in
locally advanced, recurrent, and metastatic HPC/SFT in a prospective manner.
Combination therapy with temozolomide and bevacizumab may be a
potentially clinically beneficial regimen for advanced HPC/SFT patients.
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Chapter 1
INTRODUCTION

Hemangiopericytoma and Solitary Fibrous Tumor. Tumors comprising the
spectrum of hemangiopericytoma/ solitary fibrous tumor (HPC/SFT) are rare entities
that represent a small subset of soft tissue sarcomas. Stout and Murray first
described HPC in 1942 as a distinct vascular soft tissue tumor characterized by
groups of endothelial-lined tubes and sprouts, featuring Zimmerman’s pericytes. (1)
Essential features of the diagnosis of HPC include the presence of well-developed
branching “staghorn” thick-walled vessels surrounded by connective tissue sheath,
moderate-to-high cellularity, and monotonous appearance under light microscopy
examination. (2) Classically, HPC tumors express immunohistochemical (IHC)
positivity for muscle-specific actin (HHF-35), smooth muscle actin (SMA),
tropomyosin and CD34, and negativity for desmin and h-caldesmon. (2) However,
only 10-20% of HPC display this classic expression pattern, with the majority
showing non-specific patterns. (2) Solitary fibrous tumor (SFT) was first recognized
as a unique neoplasm by Klemperer and Rabin in 1931. (Klemperer 1931) SFT
demonstrate a wide variety of histological features under light microscopy:
multinodular, partially sclerotic pattens; HPC-like patterns displaying many thin
walled staghorn branching vessels; and hypocellular, fibrous areas alternating with
a monotous, highly cellular “patternless pattern” are all seen. (3)
Immunohistochemical reactivity for CD34, CD99, bcl-2, and vimentin in the setting

2
of negativity for desmin, cytokeratins, and S-100, is a key characteristic of SFT, but
such patterns are variable across cases. (2)

The Hemangiopericytoma/ Solitary Fibrous Tumor (HPC/SFT) Spectrum: An
Evolving Concept. Much confusion and debate exist regarding the exact cell of
origin and a clear set of classification criteria for HPC and SFT. Because of the
large overlap of morphologic and clinical features between HPC and SFT, the two
entities have been frequently misdiagnosed for each other. In the most recent WHO
classification of soft tisse sarcomas, the concept of HPC as a vascular, pericytederived tumor was abandoned in favor of a fibroblastic cell of origin, thus placing
HPC more closely with SFT. (4) Therefore, the current paradigm has begun to view
HPC and SFT as a spectrum of a single entity, a viewpoint which will be adopted in
this study.

Natural history of HPC/SFT. HPC/SFT primarily occur in adults between ages 2070, with an equal frequency between men and women. (5) SFT was first identified
in the pleura and has classically been described as a neoplasm involving the
serosal surfaces, i.e. pleural, pericardial, or peritoneal. However, as more cases of
extrapleural SFT were reported, and as the diagnoses of HPC and SFT became
more aligned with each other, HPC/SFT has been described as a malignancy
affecting virtually every body site. (5-7) The most commonly affected sites include
the lower extremities, abdomen/pelvic fossa, lung/pleura, and head and neck
(especially the supratentorial meninges), with additional sites including breast,
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greater omentum, peritoneum, liver, stomach, uterus, ovary and vagina also
reported in literature. (5, 8-11)
HPC/SFT are often present for several years prior to diagnosis, and most
patients present with symptoms related to local growth. A slow-growing mass or
pain associated with locoregional pressure by the tumor are the most common. (5)
Other symptoms related to the specific tumor site include urinary retention,
constipation, (retroperitoneum and pelvic fossa), cough, dyspnea (lung and pleura),
vomiting, headache (meninges), unitlateral varicose veins or telangiectasia of
overlying skin (extremities). (5, 8) A small number of HPC/SFT patients exhibit
Doege-Potter syndrome, hypoglycemia which is thought to be mediated by
overexpression of insulin-like growth factors (IGFs) produced by the tumor. (12, 13)
Resolution of hypoglycemia occurs after tumor resection.

Clinical management of HPC/SFT. For localized disease, complete surgical
resection is often the treatment of choice. Retrospective analyses of the outcomes
of HPC/SFT patients who had undergone initial surgery show that favorable longterm outcomes can be achieved after complete surgical resection, with estimated 5year overall survival rates of 79-100%. (10, 14, 15) Patients with incomplete
surgical resection of their primary disease, however, have worse long-term
prognosis, with an estimated 10-yr overall survival of 50%.
Approximately 15-20% of primary HPC/SFT recur, either locally or distally,
after initial surgical resection. Factors that are associated with an increased risk of
developing disease recurrence include larger tumor size ( >10 cm), non-extremities
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primary tumor location, and the presence of “malignant” histology. (10, 14, 15)
Histological features of “malignant” HPC/SFT tumors include a high number of
mitotic figures ( ≥ 4/10 mitoses/HPF), cellular atypia, and the presence of necrosis
and/or hemorrhage, and tumors lacking such features are classified as “benign”. (2)
Malignant histology alone, however, does not always predict aggressive clinical
behavior. Likewise, the clinical behavior and the prognosis of “benign” tumors also
cannot be reliably predicted. (2, 4) Given this lack of clear prognostic indicators, all
HPC/SFT patients should undergo long-term follow-up, since late recurrences
(more than 20 years) can occur. (5)
Management of recurrent HPC/SFT is challenging, since no clearly effective
strategies are known. Additional surgeries should be attempted for isolated local
and/or distant lesions, but they are not always feasible nor successful. (9, 10)
Palliative radiation therapy has some role in controlling symptomatic lesions.
Stereotactic radiosurgery in recurrent, unresectable HPC/SFT of the central nervous
system may also produce some degree of durable disease control. (16)
Limited published data regarding the effectiveness of systemic chemotherapy
in HPC/SFT are available. Doxorubicin- and/or ifosfamide-based regimens have
most often been used, as well as gemcitabine-docetaxel. (10, 17-19) Systemic
chemotherapy seems to be ineffective in the management of advanced HPC/SFT. A
recent single-institution retrospective analysis of 13 HPC/SFT patients treated with
doxorubicin- or ifosfamide-based therapy showed that only 1 of 9 (11%) and 4 of 4
(0%) patients, respectively, had response. (18) The exact efficacy of standard of
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care chemotherapy regimens in advanced HPC/SFT, however, is yet poorly
defined.

Potential role of antiangiogenic therapy in HPC/SFT. HPC/SFT are highly
vascular tumor tumors, and agents that modulate or inhibit angiogenesis, therefore,
are rational and attractive therapeutic possibilities in treatment of HPC/SFT. Case
reports of advanced HPC/SFT patients who were treated with IFN-α and/or
thalidomide showed durable disease stabilization for 16-41 months. (20, 21)
Recently, several inhibitors of the vascular endothelial growth factor (VEGF)
pathway, the key mediator of angiogenesis, have been evaluated in soft tissue
sarcoma in phase II trials. A small number of HPC/SFT patients underwent
treatment with sunitinib, sorafenib, or pazopanib -- vascular endothelial growth
factor receptor (VEGFR) tyrosine kinase inhibitors – and a few patients
demonstrated durable stable disease up to 22 months. (22-25) These cases thus
suggest that angiogenesis may play a major role in HPC/SFT tumorigenesis, and
that targeting the VEGF-VEGFR pathway may produce clinically effective outcomes
in HPC/SFT patients.
Temozolomide (TMZ) and bevacizumab (BEV) combination therapy is
another regimen that offers therapeutic promise in HPC/SFT. TMZ is an oral
cytotoxic alkylating agent whose active metabolite, monomethyltriazenoimidazole
carboxamide is identical to that of dacarbazine, which has known antitumor activity
against soft tissue sarcomas. (26, 27) BEV is a recombinant monoclonal antibody
that targets VEGF. BEV has shown antitumor activity when combined with a
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number of cytotoxic chemotherapeutic agents, such that its use in combination
therapy has been approved for the treatment of metastatic colorectal, non-small cell
lung, and HER2-negative breast cancers. (28-30)
TMZ was initially approved for the treatment of recurrent high grade glioma at
a dose of 150-200 mg/m2/day for 5 consecutive days in a 28-day cycle. (31, 32)
Subsequently, alternative dosing regimens using higher cumulative concentrations
were developed in advanced high grade glioma patients. In one phase I study, 32
subjects with solid malignancies were sequentially enrolled into the following dose
cohorts: 50, 75, 100, 125, 150, and 175 mg/m2/day using a 7-days-on/7-days-off
(“dose-dense”) schedule. (33) TMZ was administered PO, in the morning of days 1
through 7 and days 15 through 21 per cycle. Treatment cycles were repeated every
28 days. TMZ was rapidly absorbed and eliminated following PO administration.
The MTD dose of 150 mg/m2 determined for this study. In a phase II study of TMZ
at 150 mg/m2/d on days 1 through 7 and 15 through 21 every 28 days, 90 patients
with recurrent gliomas were treated, achieving a 6-month PFS rate clinically
meaningful and statistically superior than that achieved with convenetional 5-day
TMZ dosing. (34) Major toxicities seen in this study, while more frequent than those
of conventional TMZ dosing regimens, were acceptable: CTCAE grade 4
hematotoxicity was only observed in 2.6% of patients, with grade 4 lymphopenia in
12% of patients. No opportunistic infections were seen. Thrombocytopenia was the
next most frequently observed toxicity, with CTCAE grade 3 and 4 toxcities
observed in 8.5% and 1.9%, respectively.
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In clinical practice, BEV is used in combination with cytotoxic chemotherapy
in doses ranging from 5 mg/kg to 15 mg/kg. The maximum tolerated dose of BEV
has not been determined. However, recruitment into the 20 mg/kg every-2-weeks
dose group of a BEV monotherapy study in patients with metastatic breast cancer
was prematurely suspended due to severe headache associated with nausea and
vomiting occurring in 4 of 16 patients (25%) in this dose group. This is the highest
dose tested in humans. The ideal biologically effective dose of BEV is unknown.
The most serious adverse events associated with BEV treatment are
gastrointestinal perforations, fistulae, hemorrhage (including tumor-associated,
mucocutaneous and intracranial), arterial and venous thromboembolic events and
wound healing complications. Increased rates of severe neutropenia, febrile
neutropenia, or infection with severe neutropenia (including some fatalities) have
been observed in patients treated with some myelotoxic chemotherapy regimens
plus BEV in comparison to chemotherapy alone. Hypertension and proteinuria are
also associated with BEV therapy, and there is some evidence from the dosefinding Phase II trials that they are likely to be dose-dependent. Information from
marketing experience identified hypertensive encephalopathy and reversible
posterior leukoencephalopathy syndrome as rare events associated with BEV
treatment. (Avastin IB)
The antitumor activity of TMZ combined with BEV is currently being studied
in a number of different dosing schedules in several phase II and III trials in
glioblastoma and malignant melanoma patients. (35) Two recently published Phase
II studies explored the safety and efficacy of TMZ in a conventional 5-day dosing
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and in a lose-dose, metronomic dosing (50 mg/m2/day for 21 days in a 28-day
cycle) combinbed with BEV 10 mg/kg with expected side effect profiles. (36, 37)
In May 2005, a patient with a recurrent meningeal HPC that was refractory to
multiple surgical resections, radiotherapy, and chemotherapy was empirically
treated with TMZ and BEV at our institution. He subsequently achieved a
radiologically evident reduction in tumor size as well as palliation of tumor-related
symptoms. This anecdotal evidence led us to treat additional patients who had
locally advanced, recurrent, or metastatic HPC/SFT not amenable to surgery with
TMZ-BEV regimen. We hypothesized that HPC/SFT patients treated with TMZ-BEV
would achieve at least similar degree of disease control, if not superior, as standard
of care chemotherapy regimens.

Hypotheses and Specific Aims. I hypothesized that HPC/SFT are a spectrum of
soft tissue tumors with unique clinical, pathological, and molecular makeup and
clinical behavior. HPC/SFT respond to unique therapeutic agents that specifically
target aberrations specific to these tumors. To test my hypothesis I designed the
following specific aims:
1. To estimate the overall response rate (ORR) and progression-free survival
(PFS) of advanced HPC/SFT patients who were treated systemic
chemotherapy, especially those with doxorubicin-based, gemcitabine-based
or paclitaxel-based chemotherapy.
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2. To describe the activity of TMZ-BEV therapy in advanced HPC/SFT and
identify potential clinicopathological factor(s) that correlate with response to
therapy and outcome.
3. To design a prospective phase II trial to determine the efficacy of TMZ-BEV
regimen in locally advanced, recurrent, and metastatic HPC/SFT.
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Chapter 2
METHODS

AIM 1: To estimate the overall response rate (ORR) and progression-free survival
(PFS) of advanced HPC/SFT patients who were treated systemic chemotherapy,
especially those with doxorubicin-based, gemcitabine-based or paclitaxel-based
chemotherapy.

Patient selection:
Patient identification. The study was approved by the University of Texas M.D.
Anderson Cancer Center institutional review board, and a waiver of consent was
granted for the proposed patient record review. All patients were initially identified
from the soft tissue tumor pathology database at the M. D. Anderson Cancer
Center. For all patients whose tumor specimens have been reviewed at the M. D.
Anderson Cancer Center from January 1993 to June 2007 by a M. D. Anderson
pathologist, the pathology reports containing the terms “hemangiopericytoma” or
“solitary fibrous tumor” within the body of the text were identified. The start time
period was chosen to reflect the time period at which the patient records were
available electronically. The pathology reports were then reviewed by me to identify
those patients whose pathologic diagnosis met the following categories: 1) HPC, 2)
SFT, 3) HPC/SFT, 4) unclassified spindle cell neoplasm/tumor, mesenchymal cell
tumor/neoplasm, or fibrosarcoma with additional comment by the pathologist
subsequently identifying the tumor as HPC and/or SFT. Patients whose pathology
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reports included HPC and/or SFT in the differential diagnosis but were ultimately
determined to have another diagnosis were excluded.
The clinical records of the selected patients were then reviewed using the
institutional electronic medical records database (ClinicStation). All clinical
encounters available in the database, as well as all available outside records which
had been scanned into the system, were reviewed. Patients who only had
pathology reports in the system without clinical notes were excluded. Patients who
had pathology reports and were seen only at their initial visit without subsequent
follow up visits at M. D. Anderson were also excluded. Pediatric patients, defined as
age at diagnosis < 18, were also excluded.

Clinicopathological Variables:
Patient demographic characteristics consisting of age at diagnosis, sex, race,
and vital status as of April 1, 2010 were collected. Primary tumor characteristics
consisting of histologic diagnosis (HPC, SFT), site, size, histologic classification
(benign, malignant, or unknown), and the presence of metastases, if any, were
collected. Site of primary tumor were categorized as central nervous system (CNS),
head & neck, lung/pleura, abdomen/pelvis, extremities, or other. Tumor site and
size were determined using pathology reports, operative reports, and/or radiologic
examinations. Available pathology reports were examined for the presence of a
high number of mitotic figures (≥ 4/10 mitoses/HPF), cellular atypia, and the
presence of necrosis and/or hemorrhage in the tumor. Tumors containing one or
more of these features were classified as malignant, and tumors lacking these
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features were classified as benign. Tumors whose pathology report did not
describe these histologic features were classified as unknown.
For patients who were initially evaluated at the MD Anderson Cancer Center
with primary localized disease, the dates and the resection status of the primary
tumor were recorded; dates of surgery, gross total resection status and/or
microscopic margin involvement were gathered from operative reports, clinical
reports, and/or pathology reports. Neo/ adjuvant radiation treatment status and
neo/ adjuvant chemotherapy status was recorded. Variables related to clinical
outcome that were collected included the development of local recurrence and/or
distant metastases, sites of recurrence, time to disease recurrence from initial
diagnosis and overall survival.
For patients who were initially evaluated at the MD Anderson Cancer Center
with locally recurrent disease or metastatic disease, treatment information regarding
the surgical resection, neo/ adjuvant radiation, and neo/ adjuvant chemotherapy
was gathered in the same fashion as the treatment of the primary tumor. Time to
disease progression from their initial treatment at MD Anderson Cancer Center and
overall disease-specific survival were also calculated.
For patients with unresectable disease who received systemic
chemotherapy, the chemotherapy regimen used, the number of cycles, the best
response reached (for patients with measurable disease only), date of disease
progression, and reasons for discontinuing therapy were collected. For patients
whose radiologic scans were available, information regarding the best response and
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disease progression was collected from direct measurement of the radiology report,
if scans were available for measurements; radiology reports, or clinic reports.
For all missing dates, all missing days of the month were coded as the 1st of
the month, and all missing months of the year were coded as January.

Radiologic Response Assessment:
All patients who had received systemic therapy were evaluated for having
their radiologic scans at baseline, during, and after treatment available in the
institution’s radiology archives. Radiologic response to treatment were assessed
using Response Evaluation Criteria In Solid Tumors (RECIST) v.1.1 (38) using
available images. For the patients whose CT and/or MRIs were in the institution’s
picture archiving and communication systems (PACS), their radiologic response to
treatment were assessed using Response Evaluation Criteria In Solid Tumors
(RECIST) v.1.1 and the Choi criteria. (39)

Statistical Analysis:
Patient characteristics were summarized using medians and ranges for
continuous variables and frequencies and percentages for categorical variables.
The response rates and the 95% confidence interval (CI) were calculated from
variance estimates. Fisher’s exact test was used to assess the association between
patient or tumor characteristics and best response.

Time to best radiologic

response was measured from the initiation of systemic therapy to development of
Choi complete response or Choi partial response (Choi criteria) or to development
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of RECIST complete response or RECIST partial response (RECIST). Progressionfree survival time (PFS) was defined as the time interval between the start of
systemic therapy and radiologic evidence of disease progression (PD) as defined by
either the Choi response criteria or RECIST, or death from any cause. Survival data
were updated on April 1, 2010 and the patients’ data were censored at that point.
Kaplan-Meier method was used to estimate the PFS and overall survival (OS). All
statistical analyses were carried out in S-plus 8.0 (TIBCO Software Inc., Somerville,
MA).

AIM 2: To describe the activity of TMZ-BEV therapy in advanced HPC/SFT and
identify potential clinicopathological factor(s) that correlate with response to therapy
and outcome

Patient selection:
The medical records of all patients with the histologic diagnoses of HPC or
SFT treated with the temozolomide-bevacizumab combination therapy at The
University of Texas M. D. Anderson Cancer Center through June 2007 were
retrospectively reviewed. All patients were initially identified from the soft tissue
tumor pathology database at the M. D. Anderson Cancer Center. The clinical
records of the selected patients were then reviewed using the institutional electronic
medical records database (ClinicStation). All clinical encounters available in the
database, as well as all available outside records which had been scanned into the
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system, were reviewed. Patients for whom radiologic scans were unavailable for
radiologic response assessment were excluded from the analysis. The following
data on patient and disease characteristics were collected: age, sex, and ethnicity;
disease characteristics, including primary tumor site and extent of disease; previous
treatment and responses; toxic effects of temzolomide and bevacizumab; and
survival. This study was approved by our institutional review board.

Radiologic Assessment:
Baseline radiologic studies had been performed up to 4 weeks prior to the
initiation of chemotherapy and follow-up scans had been performed every 8 to 12
weeks. Contrast-enhanced computed tomography (CT) or magnetic resonance
imaging (MRI), was used at the discretion of the treating physician. Radiologic
tumor response was determined as described below.
Tumor size. The longest cross-sectional dimension for each measurable
lesion was measured at the start of therapy and on each follow-up study. The sum
of the longest selected measurable lesions at each timepoint was computed for
each patient. Radiologic response was then determined by calculating the absolute
and percentage change from the baseline sum.
Tumor density (CT attenuation coefficient). In patients whose responses
were assessed with contrast-enhanced CT scans, the tumor density of each lesions
was measured in Hounsfield units (HU) by drawing a region of interest around the
margin of the entire lesion. In patients who had CTs with triphasic techniques, tumor
density was measured on scans obtained in the portal venous phase. The mean
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baseline tumor density was compared with the mean tumor density on the
subsequent studies.

Response Assessment:
Using the Choi response criteria, a complete response (CR) was defined as
the disappearance of all lesions without the appearance of new lesions. A Choi
partial response (PR) was defined as a ≥10% decrease in the sum of the target
lesions or a ≥15% decrease in tumor density in the absence of new lesions or
obvious progression of nonmeasurable disease. Choi progressive disease (PD) was
defined as a ≥10% increase in tumor size in the absence of favorable tumor density
change required to achieve Choi PR. Patients whose disease did not meet the
criteria for Choi CR, PR, or PD and who did not have tumor-related symptomatic
deterioration were classified as having stable disease (SD). Only the best response
for each patient was used in determining response rate. Response was also
assessed using Response Evaluation Criteria in Solid Tumors (RECIST) to
compare to Choi responses.

Pathology Review:
All tumor specimens had been reviewed by an M. D. Anderson sarcoma
pathologist who established the diagnoses of HPC or SFT at the time of the
patients’ initial presentation to our institution. For the purpose of this study, two
sarcoma pathologists who were blinded to the patients’ outcome re-reviewed all the
available specimens to confirm the diagnoses. Histopathologic variables including

17
size, number of mitoses, cellularity, pleomorphism, and presence of necrosis and/or
hemorrhage, were noted during the re-review if possible. Tumors were subcategorized as benign, malignant, or unknown and classified according to the 2002
WHO disease classification criteria for sarcomas.

Statistical Analysis:
Patient characteristics were summarized using medians and ranges for
continuous variables and frequencies and percentages for categorical variables.
The response rates and the 95% confidence interval (CI) were calculated from
variance estimates. Fisher’s exact test was used to assess the association between
patient or tumor characteristics and best response.

Time to best radiologic

response was measured from the initiation of temozolomide and bevacizumab
therapy to development of Choi complete response or Choi partial response.
Progression-free survival time (PFS) was defined as the time interval between the
start of temozolomide and bevacizumab therapy and radiologic evidence of PD as
defined by either the Choi response criteria or the RECIST criteria, or death from
any cause. Survival data were updated on October 15, 2009 and the patients’ data
were censored at that point. Kaplan-Meier method was used to estimate the PFS
and overall survival (OS). All statistical analyses were carried out in S-plus 8.0
(TIBCO Software Inc., Somerville, MA).
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AIM 3: To design a prospective phase II trial to determine the efficacy of TMZ-BEV
regimen in locally advanced, recurrent, and metastatic HPC/SFT.

The protocol was written in the format of National Cancer Institute’s Cancer
Therapy Evaluation Program (CTEP) Phase II Protocol Submission form and
modified . Templates can be found at http://ctep.cancer.gov/forms.

Primary Objectives:
1) To better estimate the overall response rate (ORR) for patients with unresectable
or metastatic

HPC/SFT receiving the combination of

temozolomide and

bevacizumab using the Choi criteria.
2) To assess the safety and tolerability of the combination of temozolomide and
bevacizumab in patients with unresectable or metastatic HPC/SFT.

Secondary Objectives:
1) To better estimate the ORR and disease control rate (DCR) for patients with
unresectable or metastatic HPC/SFT receiving the combination of temozolomide
and bevacizumab using RECIST.
2) To determine the time to progression (TTP) in patients with unresectable or
metastatic HPC/SFT receiving the combination of temozolomide and bevacizumab
using the Choi criteria and RECIST.
3) To determine the relationship between best response and TTP, as assessed by
Choi and RECIST.
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Primary Endpoints:
1) Overall response rate (ORR), defined as the sum of complete response (CR) and
partial response (PR) rates as assessed by the Choi criteria.
2) Safety and toxicity profile, as assessed by NCI CTCAE version 4.

Secondary Endpoints:
1) Overall response rate (ORR) as assessed by RECIST.
2) Disease control rate (DCR), defined as the sum of complete response (CR),
partial response (PR), and stable disease (SD) for the period of 6 months, assessed
using RECIST.
3) Time to progression (TTP), as assessed by the Choi criteria.
4) Time to progression (TTP), as assessed by RECIST.

Patient Selection:
Inclusion criteria:
1. Disease characteristics:
a. Diagnosis of HPC/SFT, histologically confirmed by a central
pathologist at M. D. Anderson Cancer Center:
i. unresectable disease, primary or recurrent
ii. metastatic disease
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b. Measurable disease, defined as at least one lesion that can be
measured in at least one dimension as ≥ 20 mm (or ≥ 10 mm of the
CT slice thickness is ≥ 5 mm)
i. measurable lesion must not have been irradiated ≤ 6 months
before start of therapy.
c. Must have 1 paraffin block of primary tumor and/or metastatic tissue
available prior to starting therapy
2. Prior treatment characteristics:
a. Prior surgical resection is allowed, if measurable residual disease is
present.
3. Patient characteristics:
a. Age ≥ 18 years and life expectancy of ≥ 6 months
b. ECOG performance status of 0-2
c. ANC ≥ 1,500 cells/microliter, Hgb ≥ 9 g/dl, Platelet count ≥ 125,000
cells/microliter
d. Serum creatinine ≤ 1.5 mg/dl, serum ALT, AST, total bilirubin ≤ 1.5 x
ULN
e. Signed informed consent approved by IRB prior to patient entry
f. If sexually active, patients must take contraceptive measures for the
duration of treatments

Exclusion criteria:
1. Prior treatment characteristics:
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a. Prior history of systemic chemotherapy
b. Prior radiation treatment ≤ 6 months prior to starting therapy
2. Patient characteristics:
a. Known history of hypersensitivity to dacarbazine
b. History of HIV infection
c. Pregnant or breastfeeding
d. Active infection requiring IV antibiotics or antifungal medications
e. Inadequately controlled hypertension
f. Any prior history of hypertensive crisis/ hypertensive encephalopathy
g. ≥ Grade II New York Heart Association congestive heart failure
h. History of myocardial infarction/ unstable angina < 6 months prior to
enrollment
i.

Serious cardiac arrhythmia (i.e. ventricular arrhythmia, high-grade
atrioventricular block) that requires medication during the study,
interferes with regularity of the study treatment, or is uncontrolled by
medications

j.

History of stroke/ TIA < 6 months prior to study enrollment

k. Significant vascular disease
l.

Symptomatic peripheral vascular disease

m. Evidence of bleeding diathesis/ coagulopathy with INR > 1.5
n. Major surgical procedure, open biopsy, significant traumatic injury < 4
weeks prior to enrollment
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o. Core biopsy/ other minor surgical procedure, excluding placement of
vascular access device < 7 days prior to enrollment
p. History of abdominal fiscula, GI perforation, intra-abdominal abscess <
6 months prior to enrollment
q. Serious, non-healing wound, active peptic ulcer or non-healing bone
fracture
r. Proteinuria ≥ 2+ by urine dipstick OR urine protein > 1g by 24-hour
urine collection
s. History of other primary tumors within the past 5 years, except
adequately controlled limited basal cell or squamous cell skin cancer
or carcinoma in situ of the cervix.
t. Presence of frequent vomiting or any other pre-existing medical
condition that would preclude swallowing and/or absorption of oral
medication.
u. Evidence of any psychological dysfunction, psychiatric disorder, giving
reasonable suspicion of a disease or condition that contraindicates the
use of therapy, or that may affect patient compliance with study
routines, or places the patient at high risk from treatment-related
complications.

Treatment Plan:
This protocol will utilize a single arm, phase II design. All patients will receive
temozolomide orally at 150 mg/m2 daily on days 1-7 and 15-22 on a 1 week-on, 1
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week-off schedule in a 28-day cycle. Bevacizumab will be delivered intravenously at
10 mg/kg on days 8 and 22. Patients will continue on treatment until disease
progression, severe toxicity, or if the patient’s physician felt that it was not in the
patient’s best interest to continue. A patient may discontinue treatment for an
intercurrent illness that prevented further treatment administration, if the patient
decides to withdraw from the study.
The dosing schema and route are illustrated below:
Table 1. Temozolomide-bevacizumab administration schema
REGIMEN DESCRIPTION
Agent
Temozolomide

Bevacizumab

Dose
150 mg/m2
in
tablets
5 mg/kg

Route
PO in the
a.m.

Schedule
Days 1-7,
15-21

IV over 90,
then 60
minutes

Days 8,
22

Cycle
Length
4 weeks (28
days)

Dose reductions in temozolomide are allowed, and will occur in the following
manner:

Table 2. Dose reduction guidelines for temozolomide therapy
Toxicity
Absolute Neutrophil Count
Platelet Count
CTC non-hematolotical
toxicity (except for alopecia,
nausea, vomiting)

Reduce TMZ by 1
Dose Level
< 1.0 x 109/L
< 50 x 109/L
CTC grade 3

Discontinue
TMZ
See below
See below
CTC grade 4
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Dose Level
-2

Temozolomide Dose
(mg/m2/day)
75

-1

125

0

150

Remarks
Second reduction
for toxicity
Reduction for
toxicity
Initial dose

TMZ is to be discontinued if dose reduction to < 75 mg/m2 is required or if the same
Grade 3 non-hematological toxicity (except for alopecia, nausea, vomiting) recurs
after dose reduction. For the treatment of nausea and vomiting associated with
temozolomide, patients will be prescribed antiemetic agents as necessary for
symptom control. Pain medications will also be prescribed as needed. In the cases
of grade 3 or 4 hematological toxicities, the use of hematopoietic growth factors will
be determined on an individual case base by the Principle Investigator.

Pretreatment Evaluation:
Evaluation before initiating treatment with temozolomide and bevacizumab
will include the following:
•

Complete history and physical examination, including documentation of all
measurable disease as well as signs, symptoms, concurrent medications,
and performance status.

•

Laboratory studies: CBC with differential, sodium, potassium, chloride,
bicarbonate, BUN, creatinine, glucose, calcium, magnesium, albumin,
alkaline phosphatase, total bilirubin, SGOT[AST], SGPT[ALT], PT/PTT,
urinalysis, serum pregnancy test (women of childbearing potential).
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•

12-lead EKG within 28 days prior to starting treatment.

•

Radiologic evaluation of measurable disease

•

Optional serum samples for evaluation of angiogenesis-related markers,
including but not limited to VEGF, IL-8, IL-12, PIGF, bFGF, PDGF, and
hypoxia-inducible factor at the start of treatment.

•

Patient must sign IRB-approved informed consent prior to any study-specific
procedures unless such procedures are part of the standard of care.

Evaluation During Study:
Evaluation once after initiating treatment will include the following (see also the
previous table):
•

Physical examination (including vital signs, weight, performance status):
before week 1 of each cycle prior to starting the next cycle.

•

Labs prior to day 1 1 of each cycle: CBC with differential, sodium, potassium,
chloride, bicarbonate, BUN, creatinine, glucose, calcium, magnesium,
albumin, alkaline phosphatase, total bilirubin, SGOT [AST], SGPT [ALT].
Urinalysis prior to day 1 of each cycle.

•

Radiologic evaluations will be repeated after 2 cycles of treatment. The
same radiologic method of assessment and the same technique should be
used to characterize each identified and reported lesion at baseline and
during follow-up.
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•

For the patients who underwent pretreatment serum studies, additional
serum will be analyzed during weeks 8-12 of treatment, then at the time of
disease progression or at the end of the treatment, whichever is earlier.
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Table 3. Study calendar: TMZ-BEV therapy

Temozolomide

Wk
1

Wk
2

T

Bevacizumab

Wk
3

Wk
4

T
B

Wk
5

Wk
6

T
B

Wk
7

Wk
8

T
B

Wk
9

T
B

Wk
11

X

Demographics

X

Medical history

X

Concurrent meds

X

Physical exam

X

X

X

X

Vital signs

X

X

X

X

Height

X

Weight

X

X

X

X

Performance
status

X

X

X

X

CBC w/diff, plts

X

X

X

X

a
Serum chemistry

X

X

X

X

EKG (as indicated)

X
X-------------------------------------------------------------------------------------------------X

Tumor
measurements

X

Radiologic
evaluation

X

Radiologic measurements should be performed every 8 weeks.

B-HCG

b
X

b:
c:

B

X-------------------------------------------------------------------------------------------------X

Tumor measurements are repeated every 8 weeks. Documentation
(radiologic) must be provided for patients removed from study for
progressive disease.

A:
B:
a:

Wk
12

T
B

Informed consent

Adverse event
evaluation

Wk
10

Schedule repeated until an endpoint is met

PreStudy

Off
c
Study

X
X

X
X

X
c
X

c
X

CTEP IND Agent: Dose as assigned; administration schedule
Other Agent(s): Dose as assigned; administration schedule
Albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN, calcium, chloride, creatinine, glucose, LDH, phosphorus,
potassium, total protein, SGOT [AST], SGPT [ALT], sodium.
Serum pregnancy test (women of childbearing potential).
Off-study evaluation.

Evaluation of Toxicity
Toxicities will be described according to the NCI-CTCAE Version 4.0. Dose limiting
toxicity (DLT) was defined as any grade 3 or 4 non-hematologic toxicity as defined
in the NCI CTC v4.0, even if expected and believed related to the study medications
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(except nausea and vomiting responsive to appropriate regimens or alopecia), any
Grade 4 hematologic toxicity lasting 2 weeks or longer (as defined by the NCICTCAE), despite supportive care; any Grade 4 nausea or vomiting > 5 days despite
maximum anti-nausea regimens, and any other Grade 3 non-hematologic toxicity
including symptoms/signs of vascular leak or cytokine release syndrome; or any
severe or life-threatening complication or abnormality not defined in the NCI-CTCAE
that is attributable to the therapy.

Criteria for Response
For the purposes of this study, patients should be re-evaluated for response
every 8 weeks. In addition to a baseline scan, confirmatory scans should also be
obtained not less than 4 weeks following initial documentation of objective
response, i.e. CR or PR as defined by the Choi criteria.
Response and progression will be evaluated in this study using the Choi
criteria. (39) Like the RECIST criteria, changes in only the largest diameter
(unidimensional measurement) of the tumor lesions are used to calculate change in
size. In addition, changes in CT attenuation coefficient (density) of the tumor will be
evaluated in Hounsfield Units (HU). A mean HU for each tumor density will be used
to calculate percent changes in CT density. The definition for CR, PR, SD, and PD
for Choi criteria for best response assessment is illustrated in Table 4:
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Table 4. Summary of the Choi criteria definitions
Response
CR
PR

SD
PD

Definitions
Disapperance of all lesions
No new lesions
A decrease in size of ≥ 10% or a decrease in tumor density
(HU) ≥ 15% on CT
No new lesions
No obvious progression of nonmeaserable disease
Does not meet the criteria for CR, PR, or PD
No symptomatic deterioration attributed to tumor progression
All increase in tumor size of ≥ 10% and does not meet criteria of
PR by tumor by tumor density (HU) on CT
New lesions
New intratumoral nodules or increase in the size of the existing
intratumoral nodules

Response and progression will also be assessed in this study using the new
international criteria proposed by the Response Evaluation Criteria in Solid Tumors
(RECIST) Committee. (38) Changes in only the largest diameter (unidimensional
measurement) of the tumor lesions are used in the RECIST criteria.
The best overall response (ORR) is the best response recorded from the
start of the treatment until disease progression/recurrence (taking as reference for
progressive disease the smallest measurements recorded since the treatment
started). The patient's best response assignment will depend on the achievement
of both measurement and confirmation criteria.
The duration of overall response is measured from the time measurement
criteria are met for CR or PR (whichever is first recorded) until the first date that
recurrent or progressive disease is objectively documented (taking as reference for
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progressive disease the smallest measurements recorded since the treatment
started).
The duration of overall CR is measured from the time measurement criteria
are first met for CR until the first date that recurrent or progressive disease is
objectively documented.
The duration of disease control response (DCR) is measured from the time
measurement criteria are met for CR, PR, or SD (whichever is first recorded) until
the first date that recurrent or progressive disease is objectively documented (taking
as reference for progressive disease the smallest measurements recorded since the
treatment started). This will be considered censored if the patient is lost to follow-up
or dies of a cause unrelated to the disease under study prior to the ascertainment of
progressive disease.
Stable disease (SD) is measured from the start of the treatment until the
criteria for progression are met, taking as reference the smallest measurements
recorded since the treatment started. This will be considered censored if the patient
is lost to follow-up or dies of a cause unrelated to the disease under study prior to
the ascertainment of progressive disease
Time to progression (TTP) is defined as the duration of time from start of
treatment to time of disease progression, death secondary to disease or toxicity of
treatment, or date of last follow-up. Patients who have not demonstrated
progressive disease or have died because of disease or toxicity will be considered
censored for this outcome at the last contact.
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Criteria for Removal from Study
Patients will be discontinued from treatment on the study for any of the following
events:
•

Progression of disease per Choi criteria as described previously.

•

The development of unacceptable toxicity.

•

Physician recommendation for patient removal.

•

Patient elects to discontinue further treatment on the study medications.

Statistical Considerations:
Any patient who completes two (2) or more cycles of therapy and
demonstrates CR or PR as per the Choi criteria will be considered for evaluation of
the primary efficacy endpoint of Choi ORR. Patients who demonstrate CR or PR as
assessed by the Choi criteria after cycle 2 and beyond will be considered as
“responders” for the purposes of the evaluation rule below. All other responseevaluable patients will be considered “non-responders”. Patients who are removed
from protocol therapy prior to cycle 2 because of toxicity will be considered nonresponders for the purposes of the study endpoint. Patients who are removed from
protocol therapy prior to cycle 2 for reasons other than disease progression or
toxicity will be replaced.
Any patient who completes at least four cycles of therapy and demonstrates
RECIST CR, RECIST PR, or maintains SD through cycle 4 will be considered for
evaluation of the primary efficacy endpoint of disease control rate (DCR). Patients
who demonstrate RECIST CR, RECIST PR, or maintains SD through cycle 4 will be
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considered as “responders”. Patients who experiences PD before the fourth cycle of
therapy also will be considered and will be considered as “non-resonders” All other
patients will be considered non-responders. Time to progression will be calculated
using both the RECIST and the Choi criteria. Time to progression (RECIST) and
time to progression (Choi) will then be analyzed according to the responders and
the non-responders, as previously defined by each criteria. Kaplan-Meier curves
will be constructed for each of the outcome measures. (40)
A minimum of 8 patients and a maximum of 30 patients will be enrolled. We
will monitor the trial continuously using Bayesian methodology. Denote the overall
response rate (ORR) by pR and the toxicity rate by pT. We consider an overall
response rate of less than 35% not clinically meaningful and an overall response
rate of 50% or greater would warrant further development. Therefore, we assume a
priori that the ORR has a mean of 0.35 and pR ~ Beta(0.7, 1.3).

The expected

toxicity rate is 20% and thus pT ~ Beta(0.4, 1.6) which has a mean of 0.2. A toxicity
rate of 30% or greater is considered unacceptable.

We will stop the trial for lack

of activity if Pr(pR < 0.5 | data ) < 0.99. That is, if it is very unlikely that we have
reached the target response rate of 50% then we will stop the trial for lack of
activity. We will stop the trial for excessive toxicity if Pr(pT > 0.3 | data ) > 0.8. The
resulting stopping rules are provided in Tables 5 and 6.
In order to obtain the design’s operating characteristics the trial was
simulated and the results are provided in Table 7. The goal of the design is to have
a high likelihood of stopping when a drug is too toxicity or has a low ORR. The
scenarios listed in red indicated that the drug is either too toxic or has a lack of
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activity. In scenario 1, the ORR is 60% and the toxicity is 20% and there is only at
10% chance that we will incorrectly stop the trial. However, in scenario 6 the ORR
is 25% and the toxicity rate is 30% and due to the lace of activity and unacceptable
toxicity rate the trial is stopped early 88% of the time and on average 15 patients
are enrolled. In general, the lower the ORR or the higher the toxicity rate the more
likely it is that the trial will be stopped early.

Table 5: Response stopping boundaries

The following are less-than-or-equal boundaries: a pair (n, m) means to stop if the
number of responses after treating m patients is less than or equal to n.

n (# responses)

m (# patients)

0

8

1

9

2

12

3

15

4

18

5

20

6

23

7

26

8

28

9

30

Table 6: Toxicity stopping boundaries

The following are greater-than-or-equal boundaries: a pair (n, m) means to stop if
the number of toxicities after treating m patients is greater than or equal to n.
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n (# toxicities)

m (# patients)

8

8

7

8

6

8

5

8

4

8

5

10

6

12

6

13

7

15

7

16

8

18

8

19

9

21

9

22

10

24

10

25

11

27

11

28

12

30
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Table 7: TMZ-BEV study: simulation results
Response rates in bold have indicate scenarios where the ORR has failed to
reach an acceptable level and true toxicity rates in red indicate scenarios where
the toxicity rate is too high.

Scenario

True
pR

True
pT

Pr
(Stop
Early )

Avg.
#
Pts.

Avg. # of
Respons
es

Avg. #
Toxicity

1
2
3
4
5
6
7

0.60
0.50
0.50
0.35
0.35
0.25
0.20

0.20
0.20
0.30
0.20
0.30
0.30
0.30

0.09
0.14
0.40
0.47
0.63
0.88
0.96

28
28
23
23
20
15
13

17
14
11
8
7
4
3

6
6
7
5
6
5
4

Avg.
Trial
Duration
(Months)
21.2
20.9
17.7
17.7
15.3
8.4
7.1
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Chapter 3
RESULTS

AIM 1: To estimate the overall response rate (ORR) and progression-free survival
(PFS) of advanced HPC/SFT patients who were treated systemic chemotherapy,
especially those with doxorubicin-based, gemcitabine-based or paclitaxel-based
chemotherapy

Patient and Disease Characteristics
Five hundred and fifty-three patients with the diagnosis of HPC/SFT whose
pathology specimens were evaluated that The University of Texas MD Anderson
Cancer Center between January 1993 to June 2007 were identified. They were
then evaluated for available clinical medical records at MD Anderson. Four hundred
twenty-three patients were excluded, and the remaining 128 patients were
analyzed. (Figure 1) The patients’ characteristics are summarized in Table 8.
Patients were analyzed based on the disease status at which they first presented at
MD Anderson. Patient characteristics of all patients who presented with primary
localized HPC/SFT are summarized in Table 9. Patient characteristics of all
patients who presented with locally recurrent and/or metastatic HPC/SFT are
summarized in Table 13.
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Figure 1. Evaluation schema for identification of evaluable HPC/SFT patients

Table 8. HPC/SFT patient characteristics: all patients
Characteristic
Age at First MDACC registration
median
range
Gender
male
female
Ethnicity
White
Hispanic
Black
Asian
Primary tumor site
CNS/meninges
Head/neck
lung/pleura
Abdomen/pelvis
Extremities
Other

(N=128)

(%)

54 years
19 – 88 years
71
47

55.5
44.5

101
17
4
6

78.9
13.3
3.1
4.7

39
13
17
36
15
6

30.5
10.2
13.3
28.1
11.7
4.7
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HPC/SFT – Primary Localized Disease
Seventy-nine patients who presented to MD Anderson with primary localized
disease were analyzed. Consistent with reports in the literature, the sites of primary
disease were divided evenly throughout diverse body sites, with the abdominopelvic
cavity as the most common site. Almost all patients received surgical resection as
their initial therapy. For the seventy-two patients who received surgery, most
patients had gross total resection (GTR) of their primary disease. Thirty-six (46%)
patients also received additional radiation therapy either as neoadjuvant or adjuvant
therapy. Ten (13%) patients also received chemotherapy either in neoadjuvant or
adjuvant fasion. For the seven patients who were not deemed surgically resectable,
they received palliative radiation therapy (n=1), chemotherapy (n=1), or both (n=5).
The treatment histories are summarized in Table 10.

Table 9. HPC/SFT patient characteristics: primary localized HPC/SFT

Variable

Median (range)

N
Age
Sex

N (%)
79

51 (19 - 86)
Male
Female

34 (43)
45 (57)

Primary Tumor Site
CNS/meninges
Head and Neck
Lung/Pleura
Abodmen/Pelvis
Extremities
Other

20 (25)
12 (15)
10 (13)
23 (29)
12 (15)
2 (3)
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Table 10. Treatment: primary localized HPC/SFT
N = 79

%

No
Yes

7
72

9
91

GTR
R0
R1
Incomplete resection (R2)
Unknown

26
37
6
3
7

33
47
7
4
9

Initial Treatment - Radiation Therapy
Neoadjuvant Rx
Adjuvant Rx

14
22

18
28

Initial Treatment - Chemotherapy
Neoadjuvant Rx
Adjuvant Rx

8
2

10
3

Initial Treatment - surgery

Complete resection

The majority of the HPC/SFT patients had a favorable clinical course, similar
to previously described cases in the literature. (Table 11) The median follow-up
period for the cohort following surgical resection was 45.4 months (range, 0.1 –
198.8 months). Fifty-three (67%) patients were recurrence-free at the time of this
analysis. Median recurrence free survival for the cohort was 126 months, or 10.5
years (Figure 2) Univariate analysis showed that age and tumor size were the only
significant variables for predicting recurrence-free survival (RFS). (Table 12)
Table 11. Clinical outcome: primary localized HPC/SFT
N = 79

%

Local
Metastatic
Local & Metastatic

12
13
3

15
16
4

Median Recurrence Free Survival (months)
Median Overall survival (months)

126
155

Disease recurrence (for resected pts)
Yes

No
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0.8
0.6
0.4
0.2

N.events/ N = 26 / 73
Median = 126 months

0.0

Recurrence-free survival probability

1.0

Figure 2. Recurrence-free survival curve: primary Localized HPC/SFT
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Table 12. Univariate analysis for RFS: Primary localized HPC/SFT
Variable

Coefficient

SE

Hazard Ratio

P-value

Age

0.03

0.01

1.03

0.02

Gender = Male (vs. Female)

-0.41

0.41

0.66

0.31

Tumor size (cm)

0.07

0.02

1.07

0.002

Tumor site = Extremities (vs. others)

-1.72

1.03

0.18

0.10

Tumor site = CNS (vs. others)

-0.37

0.49

0.69

0.45

Tumor site = Head & Neck (vs. others)

-1.18

0.76

0.31

0.12

Type of resection = R2 or unkonwn (vs. R0/R1/GTR)

0.20

1.04

1.23

0.85
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HPC/SFT – Locally Recurrent and Metastatic Disease
The patient characteristics of the 49 HPC/SFT patients who presented to MD
Anderson with locally recurrent and/or metastatic disease are summarized in Table
13. The most common site of metastases was liver (n=15), followed by bone (n=12)
and lung (n=8). Surgical resection remained the initial treatment of choice for the
majority of the patients, and the many of them were able to undergo successful
surgical resection. The use of additional treatment modalities, i.e. radiation therapy
and/r chemotherapy were noted more frequently, with 43% of patients undergoing
systemic therapy either as adjuvant or neoadjuvant fashion. Despite these
treatment, however, the duration of remission after their initial management at MD
Anderson was relatively short, with the median PFS of 18 months. (Figure 3) Many
patients subsequently underwent many additional courses of various therapies
including additional surgical resection, radiation therapy, and/or systemic therapy,
which is reflected by the relatively long median overall survival of 55 months (Figure
4), from the time of their initial treatment at MD Anderson.
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Table 13. HPC/SFT patient characteristics: locally recurrent and metastatic
HPC/SFT
HPC/SFT

Table 14. Treatment: locally recurrent and metastatic HPC/SFT
Surgery
Curative Intent
complete resection (R0/R1/GTR/unknown)
Incomplete resection (R2)
Radiation Therapy
Adjuvant/Neoadjuvant Rx
Palliative
Chemotherapy
Adjuvant/Neoadjuvant Rx
Palliative
Median progression-free survival

N = 49

%

43
6

87
13

9
2

18
4

21
0

43
0

18 months

43

1.0

Figure 3. Progression-free survival curve from time of treatment: locally recurrent
and metastatic HPC/SFT

0.8
0.6
0.4
0.2
0.0

Recurrence-free survival probability

N.events/ N = 41 / 48
Median = 18 months

0

50

100

150

Time (months)

0.6
0.4
0.2

N.death / N = 32 / 48
Median = 55 months

0.0

Survival probability

0.8

1.0

Figure 4. Overall survival from time of treatment: locally recurrent and metastatic
HPC/SFT
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Systemic chemotherapy in primary unresectable, locally recurrent, and/or
metastatic HPC/SFT
Thirty-eight patients with gross, measurable disease received systemic
chemotherapy for the management of advanced disease. The majority of the
patients had these that were deemed surgically unresectable, while 4 patients had
advanced disease that were potentially surgical resectable who received
chemotherapy in a neoadjuvant fashion to best reduce the size of tumors prior to
surgery. Fifteen patients received Adriamycin-based chemotherapy; 4 patients
received gemcitabine-based chemotherapy, while 4 patients received paclitaxel
therapy. All received therapy either in the first- or second-line setting. Their
responses to therapy, reason for discontinuation of therapy and time to progression
(TTP) are summarized in Table 15 and Figure 5. The median PFS for the systemic
chemotherapy cohort was 4.6 months (range, 1.3 - 15.7). For the 14 patients who
received combination therapy of temozolomide and bevaciuamb, their patient
characteristics and clinical outcome are described in detail in Aim 2.
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Table 15. Systemic therapy in advanced HPC/SFT
Characteristic
Chemotherapy
Adriamycin-based Rx
Adriamycin + ifosfamide
Adriamycin + DTIC
Adriamycin + cisplatin
Adriamycin
Gemcitabine-based Rx
Gemcitabine + Docetaxel
Gemcitabine
Paclitaxel

(N=23)

(%)

15

52
12
1
1
1

4

14
1
3

4

14

3
1
19

13
4
83

18
5

78
22

Stage
Primary locally advanced
Locally recurrent
Metastatic
Line of Therapy
First-line
Second-line
Number of cycles given
Median
Range
Reason for Stopping Therapy
Disease Progression
Toxicities
Treatment break
Surgical consolidation
XRT consolidation

4
2-10

11
5
3
3
1

48
22
13
13
4

0
19
4

0
86
14

Best Response (RECIST)
CR/PR
SD
PD
Time-to-progression
Median
Range

4.6
1.3-15.7
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Figure 5. Time-to-progression curve: systemic therapy in advanced HPC/SFT
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AIM 2: To describe the activity of TMZ-BEV therapy in advanced HPC/SFT and
identify potential clinicopathological factor(s) that correlate with response to therapy
and outcome

Patient and Disease Characteristics
Sixteen patients with advanced, recurrent, or metastatic HPC/SFT who
received temozolomide-bevacizumab therapy between May 2005 and June 2007
were identified.

Two patients for whom radiologic scans were missing were

excluded from the analysis. The remaining 14 patients’ characteristics are
summarized in Table 8. All 14 patients (9 men, 5 women) were white, and the
median age was 59 years (range, 44 – 75 years). Ten patients (71%) had HPC and
4 patients (29%) had SFT. The most common site of primary disease was the
meninges (n=6). Seven patients had metastatic disease when they began
temozolomide-bevacizumab therapy, while the remaining patients had either
primary or locally recurrent disease deemed surgically unresectable.
The majority of the patients (86%) had received prior therapy before starting
treatment with temozolomide and bevacizumab (Table 8). Five patients had
received prior systemic therapy (Table 9). Their best responses to each prior
regimen were re-assessed using the Choi criteria. They had often achieved SD and
improvement in their symptoms with the previous regimens, but none had achieved
Choi PR. The main reasons for starting temozolomide-bevacizumab therapy
included symptomatic disease, neoadjuvant treatment to potentially downstage the
tumor and enable surgical resection, and disease progression after prior therapy.
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Table 16. TMZ-BEV therapy: patient and disease characteristics
Characteristic
Age

(N=14)
median
range

(%)

59 years
44 – 75 years

Gender
male
female

9
5

64.3
35.7

white

14

100

HPC
SFT

10
4

71.4
28.6

Ethnicity
Diagnosis

Primary tumor site
meninges
6
42.9
lung/pleura
3
21.4
pelvis
3
21.4
abdominal wall
1
7.1
gluteal region
1
7.1
Tumor classification at diagnosis
benign
3
21.4
malignant
5
35.7
unknown
6
42.9
Metastatic disease
no
7
50.0
yes
7
50.0
Prior therapy
no
2
14.3
yes
12
85.7
Number of prior surgeries
0
4
28.6
1
3
21.4
2
3
21.4
3
2
14.3
4
1
7.1
6
1
7.1
Prior radiation therapy
no
7
50.0
yes
7
50.0
Number of prior systemic therapies
0
9
64.3
1
1
7.1
2
1
7.1
3
1
7.1
4
1
7.1
5
1
7.1
Abbreviations: HPC, hemangiopericytoma; SFT, solitary fibrous tumor.
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Table 17. TMZ-BEV therapy: patients’ prior systemic therapy history

Tumor
SFT
SFT

HPC

Duration
of therapy
(months)
2

Best response
(Choi)
PD

Gemcitabine-docetaxel

1

PD

Disease progression

Doxorubicin-dacarbazine

3

SD

Disease progression

Imatinib

5

SD

Disease progression

Imatinib-thalidomide

1

PD

Disease progression

Imatinib-thalidomide-etoposide

1

SD

Toxicities

Prior regimen(s)
Gemcitabine-docetaxel

Reason for stopping
therapy
Disease progression

Patient intolerance
Imatinib-thalidomide-hydrea

HPC

HPC

7

SD

Disease progression

Imatinib-hydrea

2.5

SD

Disease progression

Celecoxib*

14

SD*

Disease recurrence

Imatinib

2

PD

Disease progression

Paclitaxel*

6

SD*

Physician decision

Gemcitabine-docetaxel

3

SD

Disease progression

Endostatin

7

PD

Disease progression
Toxicities

Paclitaxel

8

SD

Disease progression

Gemcitabine

8

SD

Disease progression

* Received regimen as adjuvant therapy after R0 resection.

Treatment
All patients received temozolomide 150 mg/m2 orally on days 1-7 and days
15-21, and bevacizumab 5 mg/kg intravenously on day 8 and day 22 on a 28-day
cycle. The median number of cycles given was 7.5 (range 2.5-27). Four patients
required temozolomide dose modifications or treatment delay because of
neutropenia (n=1) or thrombocytopenia (n=3), and one of them received
granulocyte colony-stimulating factor support.
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Clinical Outcome
The overall response rate was 79% (11 patients, 95% CI 49.2%-95.3%). All
11 patients who responded had Choi PR (Table 10). Two patients (14%) achieved
Choi SD, and Choi PD was the best response in 1 patient (7%).
Response was observed as a decrease in size (n=1), in density (n=3), or in
both (n=7). (Figure 1) Ten patients (71%) demonstrated some degree of tumor
shrinkage; their median tumor size change was -10.1% (range -56.2%-15.5%). Ten
patients (71%) demonstrated at least a 15% reduction in tumor density, and the
median percent change in density was -26.2% (range -67.6%-5.4%).

For the

patients who demonstrated a Choi PR, response was seen early during treatment,
with all patients achieving PR after 2 to 4 cycles; the median time to response was
2.5 months (range 1.6-4.7 months). For the seven patients who had symptomatic
disease at the time of starting therapy, six achieved Choi PRs, which were seen
with improvements in their symptoms.
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Table 18. Overall response to TMZ and BEV

Patient
1
2
3
4
5
6
7
8
9
10
11
12
13
14
Median

Tumor
HPC
SFT
SFT
HPC
HPC
SFT
SFT
HPC
HPC
HPC
HPC
HPC
HPC
HPC

Maximum Maximum
change in change in
tumor
density
size (%)
(%)
-56.2
-42.1
-26.7
-19.5
-18.5
-13.7
-6.5
-26.9
-6.1
-3.4
4.9
0
4.6
15.5

-41.3
-67.6
-16.2
-19.1
-39.4
-83.1
-23.7
N/A*
-28.7
-60.5
-15.5
N/A*
4.4
5.4

-10.1

-26.2

Best response (Choi)
PR
PR
PR
PR
PR
PR
PR
PR
PR
PR
PR
SD
SD
PD

↓Size
↓Size
↓Size
↓Size
↓Size
↓Size
↓Size
↓Size

↓HU
↓HU
↓HU
↓HU
↓HU
↓HU
↓HU
↓HU
↓HU
↓HU

Best
response
(RECIST)
PR
PR
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD

Abbreviations: HPC, hemangiopericytoma; SFT, solitary fibrous tumor; PR, partial
response; SD, stable disease; PD, progressive disease; HU, Hounsfield units.
* Response assessment done with MRI; unable to measure density changes.
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Figure 6. CT images demonstrating a Choi PR to TMZ and BEV in a patient
with recurrent, unresectable SFT of pleura. Left, images show baseline disease
at the start of therapy. Right, images show the decrease in size and density of
disease after 27 cycles of treatment.

The overall response rate was also calculated using the RECIST criteria.
Two patients (14%) achieved a RECIST PR (95% CI 1.8%-42.8%). The remaining
12 patients all achieved RECIST SD, with 11 patients (79%) demonstrating RECIST
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SD for more than 4 months (95% CI 49.2%-95.3%). No statistically significant
associations

were

found

between

response

and

any

patient

or

tumor

characteristics, including primary tumor location (meningeal vs. non-meningeal) and
primary tumor histologic classification (benign vs. malignant vs. unknown).
At the time of analysis, the median follow-up was 34 months. The median
Choi PFS was 9.67 months (95% CI 7.31 months-not estimable), and the proportion
of patients who were progression-free at 6 months was 78.6% (Figure 7). The
median RECIST PFS was 10.8 months (95% CI 8.13 months-not estimable) (Figure
8), and the 6-month PFS was 92.9%. To date, 5 patients are alive and 4 (28.6%) of
them remain progression-free. Ten (71.4%) patients had ultimately had PD or had
died. The median OS was estimated at 24.3 months.
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Figure 7. Kaplan-Meier estimates for progression-free survival (PFS) (Choi criteria).
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Figure 8. Kaplan-Meier estimates for progression-free survival (PFS) (RECIST).
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Toxicity
Treatment was generally well tolerated, but because it was not administered
in a clinical trial setting, toxicity data were not recorded systematically. The most
notable toxic effect was myelosuppression, with neutropenia and thrombocytopenia
requiring treatment modifications and/or delays in 4 patients. Fever, chills, fatigue,
nausea, and headache were also noted.
One patient developed a pulmonary infiltrate after 20.5 cycles of
temozolomide-bevacizumab therapy, at which point therapy was withheld. A followup chest CT study 6 weeks later showed a persistent lung nodule. A biopsy of the
lesion showed inflammation and the cultures were positive for Cryptococcus. The
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patient was successfully treated with oral fluconazole, and the infection
subsequently resolved.
One patient died during treatment. The 48-year-old woman with a recurrent
HPC tumor adjacent to the cervical spine had undergone 3 prior surgeries and
radiation therapy. On day 11 of cycle 4 of temozolomide-bevacizumab therapy, she
was admitted to the hospital with Staphylococcus aureus bacteremia secondary to
infected hardware in her cervical spine.
antibiotics and the bacteremia resolved.

She was treated with intravenous
She received 2 additional cycles of

treatment but was admitted again on day 7 of cycle 6 with renal failure, altered
mental status, and hypotension. She died the following day.

AIM 3: To design a prospective phase II trial to determine the efficacy of TMZ-BEV
regimen in locally advanced, recurrent, and metastatic HPC/SFT.

The concept of this protocol was submitted to Sarcoma Alliance for Research and
Collaboration (SARC) consortium as a potential multi-institutional trial. The concept
has been accepted for submission for a full protocol proposal. The final version of
the protocol (the most recent version appears on the Appendix B) will be submitted
to SARC. Funding is being sought through Schering and/or Genentech.
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Chapter 4
DISCUSSION
.
Currently, the combination of doxorubicin and ifosfamide is the standard
systemic chemotherapy regimen for many subtypes of soft tissue sarcoma.
Gemcitabine combined with docetaxel has also emerged as a good therapeutic
choice for these patients. Although cases of HPC/SFT responding to these
chemotherapeutic agents have been sporadically reported,(10, 16-18, 41, 42) no
systematic review or clinical trial to date has identified an effective systemic regimen
for unresectable HPC/SFT.
To better understand the impact of temozolomide and bevacizumab in
HPC/SFT, we decided to expand our examination of the historical HPC/SFT cohort
of patients who had received standard-of-care systemic chemotherapy. Thus in this
largest retrospective study of advanced HPC/SFT patients to date, we show that for
patients who are not candidates for surgical resection, systemic chemotherapy is
only minimally effective for the majority of the patients. Most patients did not
achieve objective radiologic response to chemotherapy, and many progressed early
on during treatment, as evidenced by the modest median PFS of 4.6 months. The
type of chemotherapy administered did not appear to make a difference in response
or PFS, although the small number of patients examined limits us from drawing any
more definitive conclusions.
In addition, the review of our temozolomide and bevacizumab HPC/SFT
patients’ prior systemic chemotherapy regimens showed that doxorubicin,
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gemcitabine-docetaxel, and paclitaxel did not produce a radiologic response in any
of the 5 patients. Since their responses had been initially determined by RECIST,
we retrospectively re-assessed their responses using the Choi criteria, and
concluded that none of the patients had achieved a Choi PR to prior therapy, but all
5 had a PR to temozolomide and bevacizumab.
The activity of temozolomide and bevacizumab in advanced HPC/SFT
observed in this retrospective review, therefore, seems to be much more favorable
than that with standard chemotherapy regimens. In patients with locally advanced,
recurrent, or metastatic HPC/SFT who were treated with temozolomide and
bevacizumab, reductions in tumor size and/or density consistent with PRs as
assessed by the Choi criteria were evident in most patients. Several patients also
demonstrated long periods of freedom from disease progression, with 5 patients
having a time-to-progression period of ≥20 months. Our study has the typical
limitations of a retrospective analysis, including the possibilities of patient selection
bias and observer bias, a small sample size, and the lack of a systematic,
comprehensive recording of toxicities. Nevertheless, the degree of radiologic
responses and the long duration of PFS observed in out patients appear superior to
those observed in historical studies with chemotherapy regimens, as well as our
own cohort of patients as described in Aim 1.
Several studies have demonstrated that RECIST may be insensitive for
evaluating response in gastrointestinal stromal tumor (GIST) patients treated with
imatinib and the Choi criteria have recently emerged as a more sensitive tool for
assessing the degree of tumor necrosis in response to therapy in that setting.(39,
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43) Other soft tissue sarcomas, treated with cytotoxic or biologic therapies, display
similar patterns of response as GIST treated with imatinib, with patients exhibiting
long time-to-progression periods despite a lack of significant reduction in their tumor
size.(44, 45) Therefore, we chose to use the Choi criteria to assess the activity of
temozolomide and bevacizumab in HPC/SFT, because we believed that a Choi
response is more reliable for predicting potential therapeutic benefit than a RECIST
response is. Using the Choi criteria, one can detect response – or lack of response
– early in the course of treatment and thereby quickly identify potential nonresponders who may benefit from switching to another therapy. In addition, because
the Choi criteria for PD are more stringent than RECIST (≥10% increase in tumor
size), failure of therapy may also be detected earlier. This earlier detection explains
the shorter median PFS we found when using the Choi criteria than when using
RECIST.
Due to the limitations of the radiologic study archival techniques for our
historical chemotherapy cohort, we were not able to obtain Choi response rates for
the majority of the patients. Although it is theoretically possible that some of the
patients who had RECIST SD could have achieved Choi PR, the difference in PFS
(RECIST) – 4.6 months vs 9.3 months -- suggests that chemotherapy may indeed
be inferior to temozolomide and bevacizumab. The strength of our assertions are
limited by the small sample size, which does not allow us to show statistical
significance between these two groups.
Although

toxicity

data

were

not

systematically

gathered

for

the

temozolomide-bevacizumab cohort, all available clinic notes and laboratory values
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were thoroughly reviewed to capture as many side effects as possible. The majority
of the patients did not exhibit significant complications while receiving treatment as
scheduled. We did not note any serious side effects (e.g. thromboembolic events,
cardiac toxicity, or gastrointestinal bleeding) associated with bevacizumab,.
Although one patient died during treatment, we found no definitive evidence that
temozolomide and/or bevacizumab directly contributed to the immediate factors that
resulted in her death. Rather, the patient’s treating physician believed that her
overall poor performance status most likely led to her death.
Our patients on temozolomide-bevacizumab received a wide range of
number of doses of therapy. Most patients received treatment until PD or intolerable
side effects developed, but a few patients were empirically given treatment breaks
because of patient or physician preferences. It is difficult to conclude, based on the
sample size, how long temozolomide-bevacizumab therapy should be continued or
whether it could be interrupted and resumed without significantly reducing the
therapeutic benefit.

Also unclear is the potential additional benefit of radiation

therapy. Three patients with isolated sites of disease had received radiation therapy
within 4 months before or after temozolomide and bevacizumab. All had achieved
Choi PR after with their first treatment modality. Two patients were still responding
when they initiated their second treatment modality, while one was exhibiting tumor
re-growth. Despite having discontinued their last treatment 18-23 months prior to
the time of our analysis, all three continue to show a long, durable maintenance of
their responses, with PFS of 34-43 months to date. Further information regarding
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the potential synergistic effect of temozolomide-bevacizumab therapy and radiation
is needed to confirm this encouraging finding.
The exact mechanisms by which temozolomide and bevacizumab exert their
effect on HPC/SFT remain to be determined. Further studies will be needed to
better elucidate the key therapeutic targets in HPC/SFT. Analysis of our patients’
available tumor specimens for potential molecular correlative factors is currently
under development.
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Chapter 5
Potential Pitfalls, Summary and Future Directions

Potential Pitfalls
As discussed previously, our study contains all the typical limitations of a
retrospective review, including the possibilities of patient selection bias and
observer bias, a relatively small sample size, and the lack of a systematic,
comprehensive recording of toxicities. In our retrospective review of our institution’s
experience of all HPC/SFT patients, despite representing the largest published
series in the current literature, we are still limited in our abilities to draw firm
statistically significant conclusions in several clinical variables. This illustrates the
fact that HPC/SFT is a frustratingly heterogeneous clinical entity and remains a
challenge to those who wish to inconclusively define its natural history, prognosis,
and optimal treatment.
Our patient population had a higher proportion of patients who either
presented with or developed advanced disease, reflecting the referral bias to our
highly specialized cancer center. Patients who could not follow up after their initial
evaluation were also excluded, thus potentially creating another patient selection
bias. For the patients treated with temozolomide and bevacizumab, our findings are
limited by a relatively small sample size. Although the TMZ-BEV patient cohort
represent the consecutive series of patients with advanced HPC/SFT encountered
at MD Anderson, potential patient selection bias certainly exist.
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The lack of toxicities attributed to bevacizumab observed in this group may
be because of the small sample size. The true toxicity profile of this regimen may in
fact be greater than described here.

Our phase II trial design, therefore, will

specifically address this issue by making safety an independent primary endpoint.

Summary and Future Directions
To our knowledge, our report nevertheless represents the largest published
series of patients with advanced HPC/SFT treated with systemic chemotherapy to
date. We found that the combination of temozolomide and bevacizumab had a
remarkably high rate of overall response and a favorable duration of disease
control. For these rare sarcoma subtypes that lack a well-established systemic
therapeutic option, temozolomide-bevacizumab is a promising therapeutic regimen
that warrants further investigation.
The precise mechanisms by which temozolomide and bevacizumab exert
their effect on HPC/SFT are not clear. Bevacizumab has been previously combined
with chemotherapeutic agents to increase vascular permeability, leading to
subsequent synergistic cytotoxicity. Temozolomide’s activity on soft tissue
sarcomas as a single agent, although not specifically evaluated in HPC/SFT, has
not been robust. (27) Bevacizumab may enhance temozlomide’s cytotoxic activity or
may play an anti-angiogenic role by modulating the VEGF signaling pathway.
There is evidence, however, that temozolomide may possess intrinsic
antiangiogenic properties. Bevacizumab, when combined with temozolomide, may
also play a synergistic role in its antiangiogenic effect. (46) The VEGF-VEGFR
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pathway, which plays a key mediator role in angiogenesis, has recently emerged as
the key therapeutic target in HPC/SFT. The anti-VEGF receptor tyrosine kinase
inhibitors sorafenib and sunitinib were recently reported to produce Choi responses
and disease stabilization for up to 22 months in HPC/SFT patients. (23, 24, 47)
These examples also provide additional evidence that antiangiogenic approaches to
targeting HPC/SFT is a rational one. For future studies, correlative studies
consisting of deep sequencing analysis, tissue microarrays examining patterns of
alterations in key antiangiogenic pathways, as well as serum angiogenic and
cytokine profiles may determine the effects by which this regimen may exert its
effects on HPC/SFT.
Our encouraging results should be validated in a prospective trial, which
would also allow additional insight into the efficacy, safety, and biologic
mechanisms of temozolomide and bevacizumab in HPC/SFT. We have therefore
designed a single-arm phase II study which will prospectively address the true role
of temozolomide and bevacizumab. It will also be the first study dedicated solely to
this rare subtype, which will also allow us to gather information specific to the
biology of HPC/SFT. We hope that this study will not only provide a potential new
therapy for HPC/SFT, but also provide invaluable insight regarding the biological
drivers of this disease entity and additional potential therapeutic targets.
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